About Acesion Pharma
Acesion Pharma is a Healthcare company based in Copenhagen (Denmark) founded in 2011 by Morten Grunnet. Drugs for atrial fibrillation are developed targeting SK ion channels. Acesion Pharma has raised $68.42 million across 10 funding rounds from investors including European Union, Canaan and Innovationsfonden. The company has 12 employees. Acesion Pharma has completed 1 acquisition, including Coinify. Acesion Pharma was last valued at $28.49 million in September 2020. Its chief executive, as recorded, is Frans Wuite. Acesion Pharma offers products and services including AP30663 and AP31969. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Arrhythmia. Its legal entity is Acesion Pharma ApS.
Company details
Acesion Pharma was founded in 2011 in Copenhagen, Denmark, as a biotech firm focused on cardiac arrhythmia treatments. Atrial fibrillation, the most common arrhythmia, is addressed through drugs targeting SK ion channels to regulate heart rhythm. The lead candidate, AP30663, has completed phase 1 clinical trials. Operations emphasize drug development in the cardiovascular sector, with activities based in Europe.
- Headquarters Copenhagen, Denmark
- Employees 12
- Founders Morten Grunnet
- Stage Minicorn
- SectorsHealthcare
- Website acesionpharma.com
- Social LinkedIn X
- Legal Name Acesion Pharma Aps
- Net Profit-$6.18 M (USD)-64as on Dec 31, 2019
- EBITDA-$7 M (USD)-53as on Dec 31, 2019
- Total Equity Funding$68.42M (USD)
in 10 rounds
- Latest Funding Round$47M (USD), Series B
Sep 2023
- InvestorsEuropean Union
& 8 more
- Employee Count12
- Investments & Acquisitions
Products & Services of Acesion Pharma
Acesion Pharma offers a comprehensive portfolio of products and services, including AP30663 and AP31969.
Inhibitor targeting SK ion channel for atrial fibrillation treatment.
Novel therapy for managing atrial fibrillation symptoms effectively.
Funding Insights of Acesion Pharma
Acesion Pharma has successfully raised a total of $68.42M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $47 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $68.42M
- Total Rounds 10
- Last Round Series B — $47M
- First Round $72,368
(Jan 2011)
- Investors Count 9
All 10 funding rounds of Acesion Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $47M | Series B | – | Canaan, Alpha Wave Global | |
| Sep 2020 | $2.34M | Series B | $28.49M | – | – |
| May 2019 | Series B | $22.77M | FC Capital | – | |
| Mar 2019 | $747,991 | Grant | – | – | |
| Nov 2016 | $12.48M | Series B | – | Wellcome Trust, Novo Holdings | – |
| Sep 2015 | $655,179 | Grant | – | – | |
| Dec 2014 | $5.23M | Series A | – | Novo Holdings | |
| Dec 2013 | $2.65M | Grant | – | – | |
| Apr 2013 | $1.29M | Seed | – | – | – |
| Jan 2011 | $72,368 | Seed | – | Novo Holdings | – |
| Date | Valuation | Stage |
|---|---|---|
| Sep 2020 | $28.49M | •••••••• |
| May 2019 | $22.77M | •••••••• |
Last known valuation $28.49M (Sep 2020). 9 investors in total: 9 institutional.
Investors in Acesion Pharma
Acesion Pharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Canaan and Innovationsfonden.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Venture capital firm focused on growth-stage companies | alphawaveglobal.com | New York, United States | ||
| globalbioaccess.com | ||||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Early stage VC firm investing in Denmark | 2014 | innovationsfonden.dk | Aarhus, Denmark | |
Seed-stage life sciences investments are made in the US. | broadviewventures.org | Boston, United States | ||
Provides private debt and direct lending solutions for businesses and investors. | 2012 | fccapital.com.au | Sydney, Australia | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Acesion Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acesion Pharma
7 people are tracked at Acesion Pharma (7 in leadership); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Morten Grunnet | Co-Founder & CSO | Leadership |
Frans Wuite | CEO | Leadership |
Michael Flaschen | Chief Business Officer | Leadership |
Torgeir Vaage | Chief Financial Officer | Leadership |
Ulrik Sørensen | COO and Co-Founder | Leadership |
Anders Gaarsdal Holst | Chief Executive Officer | Leadership |
Birgitte Vestbjerg | Director Clinical Operations | Leadership |
Complete people profiles for Acesion Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acesion Pharma
Acesion Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Coinify.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Crypto-based payment solution for consumers and businesses | coinify.com | Copenhagen, Denmark | 2014 | Aug 2022 | •••• |
Complete acquisition details for Acesion Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Acesion Pharma
5 dated milestones of Acesion Pharma across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Acesion Pharma is founded.
- Funding First funding round of $72K.
- Milestone Reaches Minicorn status.
- Acquisition Acquires Coinify.
- Funding Latest funding round, Series B, of $47.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acesion Pharma
Complete news archive for Acesion Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acesion Pharma
Acesion Pharma was founded in 2011.
Acesion Pharma is headquartered in Copenhagen, Denmark.
Frans Wuite is the CEO of Acesion Pharma, as recorded in our data.
Acesion Pharma is a funded company, having raised a total of $68.42M across 10 funding rounds to date. The company's 1st funding round was a Seed of $72.37K, raised on Jan 2011.
Acesion Pharma has 12 employees.
Acesion Pharma was founded in 2011 in Copenhagen, Denmark, as a biotech firm focused on cardiac arrhythmia treatments. Atrial fibrillation, the most common arrhythmia, is addressed through drugs targeting SK ion channels to regulate heart rhythm. The lead candidate, AP30663, has completed phase 1 clinical trials. Operations emphasize drug development in the cardiovascular sector, with activities based in Europe.
Acesion Pharma offers AP30663 and AP31969.
Acesion Pharma has made 1 acquisition, including Coinify.
Acesion Pharma has 9 investors. Key investors include European Union, Canaan, Innovationsfonden, Alpha Wave Global, and Global BioAccess.
The valuation of Acesion Pharma is $28.49M as of Sep 2020.
Acesion Pharma operates through Acesion Pharma Aps.